Phase 3: Optimize both (weeks 9-16) Increase AOD 9604 to 300-500mcg daily based on tolerance
Personnel must not extrapolate beyond-use periods from other peptides or from generic pharmaceutical literature
Stage 2: Why MEHP Persistence Governs the Half-Life Calculation MEHP is the regulatorily binding intermediate, not just a transient
After 24 weeks of treatment, significant reductions in neuropathy symptom and disability scores and in neurophysiological parameters were seen in both groups, with no difference between the two drugs safety-wise
Do these peptides require refrigeration
The honest answer is that both very low and, in rare cases, very high B12 levels may be linked to shedding, but the strongest evidence points to deficiency as the real concern, not normal supplements